Vital Signs Research Series
What NHS payers
want pharma
to understand.
Better engagement starts with understanding the people making NHS decisions - and the realities they face.
Our Vital Signs research series brings together candid perspectives from senior NHS payers on what builds trust, how they assess value and what stands between approval and routine prescribing. Explore where pharma engagement falls short, what practical support the NHS needs and why pharma must reach the people who shape local decisions and put them into practice.
New Research
Just publishedVital Signs 2.0:The Implementation Gap
Approved. But what happens next?
Drawing on the views of 30 senior NHS payers, this report explores what holds back routine prescribing, the support local teams need and the people pharma must reach to help move implementation forward.
Vital Signs 1
Vital Signs:Decoding UK Payers
What does useful pharma engagement look like from the NHS perspective?
Fifty senior NHS payers share what builds trust, how they define value and why understanding local pressures matters. Discover what they want industry to do differently.